Oxymetazoline: Difference between revisions
| Line 12: | Line 12: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: Safety during pregnancy has not been studied. | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Not available | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: Not needed | ||
*Pediatric: | *Pediatric: Not needed | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*Adult: | *Adult: Not needed | ||
*Pediatric: | *Pediatric: Not needed | ||
==Contraindications== | ==Contraindications== | ||
Revision as of 19:15, 12 August 2016
Administration
- Type: Decongestant; Adrenergic Agonist Agent; Imidazoline derivative
- Dosage Forms: Solution; Nasal spray
- Routes of Administration: Intranasal
- Common Trade Names: 12-Hour Nasal Relieve Spray, Afrin, Mucinex, Distran, Neo-synephrine
Adult Dosing
- Instill 2-3 sprays for each nostrils twice daily for ≤3 days
Pediatric Dosing
- Children ≥6 years: Instill 2-3 sprays for each nostrils twice daily for ≤3 days
Special Populations
- Pregnancy Rating: Safety during pregnancy has not been studied.
- Lactation risk: Not available
Renal Dosing
- Adult: Not needed
- Pediatric: Not needed
Hepatic Dosing
- Adult: Not needed
- Pediatric: Not needed
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion: